Clinical data | |
---|---|
Trade names | Ypozane |
Other names | TZP-4238; Gestoxarone acetate; 2-Oxachloromadinone acetate; 17α-Acetoxy-6-chloro-2-oxa-6-dehydroprogesterone; 17α-Acetoxy-6-chloro-2-oxapregna-4,6-diene-3,20-dione |
Routes of administration | By mouth ( tablets) |
Drug class | Steroidal antiandrogen; Progestogen; Progestin; Progestogen ester |
Pharmacokinetic data | |
Protein binding | Osaterone acetate: 90% 15β-Hydroxyosaterone acetate: 80% [1] (Both mainly to albumin) [1] |
Metabolism | Liver [1] |
Metabolites | 15β-Hydroxyosaterone acetate [1] |
Elimination half-life | Dogs: 80 hours to 197 ± 109 hours [1] [2] |
Excretion |
Bile: 60%
[1] Urine: 25% [1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ECHA InfoCard | 100.215.750 |
Chemical and physical data | |
Formula | C22H27ClO5 |
Molar mass | 406.90 g·mol−1 |
3D model ( JSmol) | |
| |
|
Osaterone acetate, sold under the brand name Ypozane, is a medication which is used in veterinary medicine in Europe in the treatment of enlarged prostate in dogs. [1] [3] [4] It is given by mouth. [1]
Osaterone acetate is an antiandrogen, and hence is an antagonist of the androgen receptor, the biological target of androgens like testosterone and dihydrotestosterone. [1] It is also a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. [1]
Osaterone acetate was introduced for veterinary use in 2007. [5] It is marketed in Europe. [6] [1]
Osaterone acetate is used in veterinary medicine in Europe in the treatment of benign prostatic hyperplasia (BPH) in dogs. [1] [3] [4] It has been found to produce remission of clinical symptoms of BPH in 83% of dogs for six months after a single one-week course of treatment, [7] and can be used long-term. [4]
Osaterone acetate comes in the form of 1.875 mg, 3.75 mg, 7.5 mg, and 15 mg oral tablets for veterinary use. [1]
Side effects of osaterone acetate include diminished sperm quality (for up to 6 weeks post-treatment), transient elevation of liver enzymes (caution should be observed with known liver disease), vomiting, diarrhea, polyuria/ polydipsia, lethargy, and hyperplasia of the mammary glands. [8] It can also decrease cortisol levels, interfere with adrenocorticotropic hormone response, induce or exacerbate adrenal insufficiency, and exacerbate diabetes mellitus. [9] [8]
Osaterone acetate is a steroidal antiandrogen, progestin, and antigonadotropin. [1] It has virtually no estrogenic or androgenic activity. [3] Its side-effect profile indicates that it possesses clinically relevant glucocorticoid activity. [9] [8] An active metabolite of osaterone acetate, 15β-hydroxyosaterone acetate, has potent antiandrogenic activity similarly to osaterone acetate. [1] Osaterone acetate treats BPH in dogs by reducing the actions of androgens in the prostate gland. [1]
The major active metabolite of osaterone acetate is 15β-hydroxyosaterone acetate. [1] Osaterone acetate has a long biological half-life of 80 hours to 197 ± 109 hours in dogs. [1] [2]
Osaterone acetate, also known as 2-oxachloromadinone acetate, as well as 17α-acetoxy-6-chloro-2-oxa-6-dehydroprogesterone or 17α-acetoxy-6-chloro-2-oxapregna-4,6-diene-3,20-dione, is a synthetic pregnane steroid and a derivative of progesterone and 17α-hydroxyprogesterone. [6] It is a derivative of the less potent chlormadinone acetate. [3] The medication is the C17α acetate ester of osaterone. [6]
Osaterone acetate was introduced for veterinary use in Europe under the brand name Ypozane in 2007. [6] [5] [1]
Osaterone acetate is the generic name of the drug. [6] Osaterone is the INN of the deacetylated parent compound. [6]
Osaterone acetate is marketed under the brand name Ypozane by Virbac. [6]
Osaterone acetate is available widely throughout Europe, including in Belgium, Finland, France, Germany, Italy, the Netherlands, Norway, Poland, Sweden, Switzerland, and the United Kingdom. [6]
Osaterone acetate was also investigated in Japan in the treatment of prostate cancer and BPH in humans but was ultimately never marketed for such purposes. [3] [10]